AMG Announces Partnership with Forbion
27 Junho 2023 - 9:00AM
Affiliated Managers Group, Inc. (NYSE: AMG), a leading partner to
independent investment management firms globally, has entered into
a definitive agreement to acquire a minority equity interest in
Forbion Group Holding B.V. (“Forbion”). After the closing of the
transaction, Forbion partners will continue to hold a significant
majority of the equity of the firm and direct its day-to-day
operations.
Forbion is a leading pan-European venture capital and growth
equity firm focused on investing in high-quality life sciences
companies across all stages of their development. With
approximately €3 billion in assets under management, Forbion
provides capital and expertise to life sciences companies, enabling
the development of new therapeutics that can impact the future of
medicine. Led by co-founders and Managing Partners Sander Slootweg,
Geert-Jan Mulder, and Martien van Osch, Forbion’s seasoned team has
delivered excellent returns for clients for more than two decades,
and continues to support companies delivering breakthrough drug
therapies to the global market.
“We are very pleased to partner with Forbion, a leader in life
sciences investing – a sector with robust client demand trends and
meaningful societal impact,” said Jay C. Horgen, President and
Chief Executive Officer of AMG. “AMG’s partnership approach
continues to attract outstanding firms seeking to preserve their
independence and entrepreneurial cultures, and to benefit from
collaboration with a strategic partner that can magnify their
success. Our partnership with Forbion broadens our
participation in both private markets and the life sciences sector,
further diversifying our business and enhancing our long-term
growth prospects. I am pleased to welcome Sander, Geert-Jan,
Martien, and their partners to our Affiliate group.”
“We are excited to partner with AMG, as its unique approach
enables us at Forbion to preserve our investment independence and
operational autonomy,” said Sander Slootweg, co-founder and
Managing Partner of Forbion. “Our entrepreneurial and
investment-centric culture has been critical to our success, and
with our respective firms’ long-term partnership orientation,
Forbion and AMG share a deep cultural alignment. As we continue to
invest in high-quality life sciences companies, we are confident
that our strategic partnership with AMG will enhance our ability to
further expand our investment platform, diversify our client base
as we access new geographies and channels through AMG’s capital
formation capabilities, and build an enduring, multi-generational
firm.”
The terms of the transaction were not disclosed. The transaction
is expected to close in the second half of 2023.
About AMG
AMG is a leading partner to independent investment management
firms globally. AMG’s strategy is to generate long-term value by
investing in a diverse array of high-quality independent
partner-owned firms, through a proven partnership approach, and
allocating resources across AMG’s unique opportunity set to the
areas of highest growth and return. AMG’s innovative partnership
approach enables each Affiliate’s management team to own
significant equity in their firm while maintaining operational and
investment autonomy. In addition, AMG offers its Affiliates growth
capital, distribution, and other strategic value-added
capabilities, which enhance the long-term growth of these
independent businesses, and enable them to align equity incentives
across generations of principals to build enduring franchises. As
of March 31, 2023, AMG’s aggregate assets under management were
approximately $668 billion across a broad range of differentiated
investment strategies. For more information, please visit the
Company’s website at www.amg.com
About Forbion
Forbion is a dedicated life sciences venture capital firm with
offices in The Netherlands, Germany, and Singapore. Forbion invests
in life sciences companies that are active in the biopharmaceutical
space, managing €3 billion across multiple fund strategies that
cover all stages of biopharmaceutical drug development. The firm’s
current team consists of more than 30 life sciences investment
professionals that have built an impressive performance track
record since the late nineties with investments in 95 companies
across 8 funds. Forbion’s record of sourcing, building and guiding
life sciences companies has resulted in many breakthrough therapies
and valuable exits. In addition to its financial return objectives,
Forbion selects investments that will positively affect the health
and well-being of patients. The firm is a signatory to the United
Nations Principles for Responsible Investment. More information can
be found at www.forbion.com
Certain matters discussed in this press release may constitute
forward-looking statements within the meaning of the federal
securities laws, and could be impacted by a number of factors,
including those described under the section entitled “Risk Factors”
in AMG’s most recent Annual Report on Form 10-K, as such factors
may be updated from time to time in the Company’s periodic filings
with the SEC, which are accessible on the SEC's website at
www.sec.gov. AMG undertakes no obligation to publicly update or
review any forward-looking statements, whether as a result of new
information, future developments or otherwise, except as required
by applicable law. From time to time, AMG may use its website as a
distribution channel of material Company information. AMG routinely
posts financial and other important information regarding the
Company in the Investor Relations section of its website at
www.amg.com and encourages investors to consult that section
regularly.
AMG Investor Relations: Patricia FigueroaAMG Media Relations:
Ann Imes
+1 (617) 747-3300ir@amg.com pr@amg.com
Affiliated Managers (NYSE:AMG)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Affiliated Managers (NYSE:AMG)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024